Last checked at 26 Feb 2014 07:00
For immediate release | 26 February 2014 |
Futura Medical plc
("Futura" or "the Company")
Notice of Preliminary Results
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology will announce its preliminary results for the year ended 31 December 2013 on Friday 28 March 2014.
A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
For more information, or to register attendance, please contact Buchanan on 020 7466 5000.
For any further information, please contact:
Futura Medical plc | |
James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
mail to: james.barder@futuramedical.com |
www.futuramedical.com |
Cenkos Securities plc | |
Bobbie Hilliam | Tel: +44 (0) 20 7397 8900 |
For media enquiries, please contact: | |
Buchanan | |
Mark Court / Fiona Henson / Sophie Cowles | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com